AstraZeneca, Daiichi Sankyo’s drug shows promise in breast cancer patients in trial

Alexis Juanita

Roland Magnusson AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) said on Thursday that their medicine datopotamab deruxtecan (Dato-DXd) showed durable efficacy in patients with a type of breast cancer in an early stage study. The two-part, phase 1 trial, dubbed TROPION-PanTumor01, is evaluating datopotamab deruxtecan in patients with advanced solid […]

Novartis radioligand therapy Pluvicto gets approval in EU for advanced prostate cancer

Alexis Juanita

artJazz The European Commission (EC) approved Novartis (NYSE:NVS) Pluvicto to treat certain patients with advanced prostate cancer. The radioligand therapy was approved in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition to treat adult patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer […]